Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
AO-176 / Arch Oncology
NCT04445701: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma	Completed	1/2	10	US	AO-176, AO-176 + Dex, AO-176 + Dex + Bort	Arch Oncology	Multiple Myeloma	08/22	11/22
KEYNOTE-C49, NCT03834948: AO-176 in Multiple Solid Tumor Malignancies	Completed	1/2	57	US	AO-176, AO-176 + Paclitaxel, AO-176 + Pembrolizumab	Arch Oncology, Merck Sharp & Dohme LLC	Solid Tumor	11/22	02/23
Ti-061 / Arch Oncology
No trials found
Undisclosed SIRP alpha mab / Arch Oncology
No trials found